Stock Ratings / Health Care / BCRX / forecast

VCEL (67) MESO (60) VIR (31) ALVO (58) ⌘ Pro Terminal →

BioCryst Pharmaceuticals Inc. (BCRX) 12-Month Stock Forecast & Price Target Cone

$8.52 +1.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

BioCryst Pharmaceuticals Inc. (BCRX) earns a Roarable Rating of B+ (Buy) with 78/100 RQD Confidence. High-quality cash engine (steady margins, 85% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $2.18B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A- · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BCRX)Realized 20D OHLCV Swing Band: ±8.2%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your BCRX Position Size: $10,000

Shares at $8.52: 1173.7 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $6.99

$8,204

$-1,796 (-18.0%)

12M Consensus BaseTarget $9.29

$10,904

+$904 (+9.0%)

12M Bull Case BreakoutTarget $11.78

$13,826

+$3,826 (+38.3%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (43 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 32● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	OUTPERFORM	$10	74%	A
Goldman SachsSector Coverage Lead	STRONG BUY	$11	69%	B
JP MorganUS Large-Cap Research	HOLD	$8	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (BCRX Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BCRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.99%▼ DESCENDING CHANNEL

2026-10-30O $8.55H $8.62L $8.38C $8.52VOL 3.53M

RES: $9.19SUP: $7.49SMA50: $8.63SMA200: $8.75

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BCRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BCRX Butterfly Map → + Track BCRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-4.8%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BCRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BCRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BCRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BCRX)

Health Care Rank #22 of 1016 ⚔️ VCEL vs BCRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BCRX vs. VCEL, MESO, VIR, ALVO)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BioCryst Pharmaceuticals Inc. (BCRX) ranks #22 by composite RQD confidence (78/100, grade B+) and #249 by equity capitalization ($2.18B). Within this direct 5-issuer industry benchmark cohort, BCRX leads on earnings valuation at 8.3x trailing P/E, while BCRX leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. BCRX currently leads its immediate peer cohort in composite quantitative strength at 78/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BCRX ACTIVE BioCryst Pharmaceuticals Inc.	B+	78/100	8.3x	—	85.0%	+1.79%	$2.18B	Benchmark Subject
VCEL Vericel Corporation	C+	67/100	133.0x	74.4%	3.4%	+4.43%	$2.20B	/vcel-vs-bcrx →
MESO Mesoblast Limited	C-	60/100	—	—	—	+17.03%	$2.04B	/meso-vs-bcrx →
VIR Vir Biotechnology Inc.	E	31/100	—	96.0%	-35.0%	-1.51%	$2.01B	/vir-vs-bcrx →
ALVO Alvotech	D+	58/100	—	—	—	-1.01%	$1.91B	/alvo-vs-bcrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000882796

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioCryst Pharmaceuticals Inc. (BCRX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $263.9M, operating cash flow of $347.4M, and free cash flow of $347.4M (+767.8% YoY). On the balance sheet, BCRX closed FY2025 with $514.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$263.9M	$347.4M	$347.4M	$514.2M	$0
FY2024 (FY)	2024-12-31	$0	-$88.9M	-$52.0M	-$52.0M	$490.4M	$314.9M
FY2023 (FY)	2023-12-31	$0	-$226.5M	-$95.1M	-$95.1M	—	—

3. BCRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BCRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 78/100 at a spot price of $8.52 (+1.79% 1D, market cap $2.18B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, BCRX ranks #22 in composite RQD confidence.

How does BCRX compare to VCEL and MESO in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BCRX carries a Roarable B+ (78/100 RQD), trailing P/E of 8.3x, gross margin of —, and ROIC of 85.0%. By comparison, VCEL (Vericel Corporation) holds a C+ grade (67/100 RQD, P/E 133.0x, ROIC 3.4%, cap $2.20B) and MESO (Mesoblast Limited) posts a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $2.04B). Among the 5-stock peer group, BCRX leads on earnings multiple (8.3x) while BCRX leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BCRX?

Per BCRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000882796), BioCryst Pharmaceuticals Inc. generated $0 in revenue, $263.9M in net income, and $347.4M in free cash flow against $514.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BCRX trading relative to its 50-day, 200-day, and 52-week technical levels?

BCRX last traded at $8.52 (+1.79% on volume of 4,519,653 shares), positioning the stock -1.27% below its 50-day simple moving average ($8.63) and -2.63% below its 200-day simple moving average ($8.75). Across its 52-week range of $6.23 to $11.22, BCRX sits at the 45.9% percentile with a 14-day RSI of 54.8 (NEUTRAL RANGE) and an implied next-earnings move of ±8.2% ($7.82 to $9.22).

BCRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is BCRX's 12-month stock price target?

BioCryst Pharmaceuticals Inc. (BCRX) carries a 12-month consensus base price target of $9.29 (+9% from $8.52), with a bull-case target of $11.78 and a bear-case floor of $6.99.